Primary Prevention Long-term Registry Study in OSA and Hypertension. Survival Analysis 2010-2022

Twin Threat of OSA and Hypertension on Mortality/CV-risk and Protective Effect by Positive Airway Pressure Treatment.

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06930989

Acronym

DISCOVERY-HT

Enrollment

148467

Registered

2025-04-16

Start date

2025-01-01

Completion date

2025-04-30

Last updated

2025-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension, MACE, OSA - Obstructive Sleep Apnea, PAP, Survival Analysis

Keywords

Primary CV prevention, hypertension, OSA, PAP

Brief summary

Hypertension and obstructive sleep apnea (OSA) are both common conditions that independently increase the risk cardiovascular disease including atrial fibrillation, ischemic heart disease, heart failure and stroke. OSA is also an independent promoter of hypertension development and poorly controlled hypertension is overrepresented in OSA. Finally, HT and OSA share many risk factors including obesity, and several lifestyle factors. Altogether, these links contribute to a high prevalence of patients with both disorders. The investigators suspect participants with HT and OSA are at even higher CV risk and may get their first CV event earlier in life. Comparison between HT and OSA participants vs HT alone, OSA alone or healthy controls has not previously been investigated in large studies. Thus, the investigators aim to investigate long-term risk of major cardiovascular events (MACE) or death comparing these groups in registry data between 2010-2022 in Sweden. The investigators will also investigate the protecting effect of positive airway pressure (PAP) on the OSA related CV risk increase and how many hours/night of PAP use is needed to get any protective effects.

Detailed description

Please see attached analysis plan

Interventions

DEVICEPositive airway pressure (PAP)

Intervention as part of routine clinical care. Data from national registries.

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Adult patients starting PAP treatment for OSA in the swedevox registry between 2010-2021 with and without hypertension. Randomly selected controls with and without hypertension from the general population.

Exclusion criteria

* Patients with manifest cardiovascular disease (stroke, ischemic heart disease, cardiac failure or atrial fibrillation at baseline). * Patients with kidney failure at baseline. * Patients with malignant cancer at baseline. * Subjects with missing data on any of the main variables in the fitted models.

Design outcomes

Primary

Measure	Time frame	Description
Major cardiovascular event (MACE)	First event during follow-up 2010-2022	Major cardiovascular event (MACE) including CV death
Age at first MACE	First event during follow-up 2010-2022	mean age at first MACE for the groups
All cause death	2010-2022	death from any cause during follow-up

Secondary

Measure	Time frame	Description
Risk reduction with PAP	2010-2022	Survival analysis between both OSA groups only stratified by PAP adherence (hours/night)

Countries

Sweden

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026